Month: September 2020

Sep 23 2020

Uncategorized

Trending News: Schizophrenia Therapeutic Market Growth, Size, Analysis and Trends to 2026| Eli Lilly, Johnson and Johnson, Pfizer

by Clinical Editor

No Comments

Schizophrenia Therapeutic Market is expected to grow significantly over next few years and generate considerable market for Schizophrenia Therapeutic . Market Report Expert has recently published a …

Sep 22 2020

Uncategorized

American Psychiatric Association Publishes Updated Practice Guidelines for the Treatment of Schizophrenia – Psychiatry Advisor

by Clinical Editor

No Comments

American Psychiatric Association Publishes Updated Practice Guidelines for the Treatment of Schizophrenia  Psychiatry Advisor

Sep 22 2020

Uncategorized

Trending News: Schizophrenia Therapeutic Market Growth, Size, Analysis and Trends to 2026| Eli Lilly, Johnson and Johnson, Pfizer

by Clinical Editor

No Comments

Schizophrenia Therapeutic Market is expected to grow significantly over next few years and generate considerable market for Schizophrenia Therapeutic . Market Report Expert has recently published a …

Sep 22 2020

Uncategorized

Researchers reveal sex differences in association between symptoms of schizophrenia and superoxide dismutase

by Clinical Editor

No Comments

Schizophrenia is a disabling psychiatric disorder characterized by positive symptoms, such as hallucinations and delusions, negative symptoms, such as decreased expression ability, and cognitive …

Sep 22 2020

Uncategorized

NIH public-private partnership to advance early interventions for schizophrenia

by Clinical Editor

No Comments

Effort is part of the Accelerating Medicines Partnership to promote development of effective, targeted treatments.

Sep 22 2020

Uncategorized

Factors predictive of psychopathy and schizophrenia are already present in newborn infants’ brain cells

by Clinical Editor

No Comments

Would you prefer to be told that your newborn is likely to grow up into a psychopath? Or that they may develop schizophrenia? What if, after receiving a positive result,...

Sep 22 2020

Uncategorized

Boehringer’s schizophrenia med boosts cognition in phase 2

by Clinical Editor

No Comments

Boehringer Ingelheim’s schizophrenia hopeful hit the mark in a phase 2 study, helping patients overcome cognitive impairment that can affect everyday tasks, such as remembering important dates or …

Sep 21 2020

Uncategorized

Researchers reveal sex differences in association between symptoms of schizophrenia and superoxide dismutase

by Clinical Editor

No Comments

Schizophrenia is a disabling psychiatric disorder characterized by positive symptoms, such as hallucinations and delusions, negative symptoms, such as decreased expression ability, and cognitive …

Sep 21 2020

Uncategorized

NIH public-private partnership to advance early interventions for schizophrenia

by Clinical Editor

No Comments

Effort is part of the Accelerating Medicines Partnership to promote development of effective, targeted treatments.

Sep 21 2020

Uncategorized

NIH to promote early intervention for schizophrenia via public-private partnership

by Clinical Editor

No Comments

The National Institutes of Health announced a new public-private partnership, the goal of which is to meet the urgent need for early therapeutic interventions for people at risk of developing...